NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Nirmal Bang Report
La Opala RG Ltd.’s Q4 FY24 operating performance came significantly below our expectations on account of lower revenue. Reduced consumer spending and channel correction measures by the company impacted revenue performance, as per management.
Despite ~19% YoY decline in revenue in FY24, the management has guided for ~15% revenue growth during FY25, lower than our estimate. Also, considering the higher year-end inventory (up 33% YoY) on the books, La Opala is not going with the earlier plan of debottlenecking at Sitarganj in FY25. Borosilicate in-house manufacturing has already been pushed to next year.
While the commentary on growth is not reassuring for FY25, we believe risk-reward is still favourable. Therefore, after earnings revision, we maintain Buy with a revised target price of Rs 370 (25 times PE on FY26E).
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
RECOMMENDED FOR YOU

WhatsApp's Upcoming Feature Will Allow You To Pose Questions In Channels, Get Opinions From Followers


Financial Services Q4 Review: NBFCs Outpace Banks With Strong Credit Growth, Evolving Funding Mix: DRChoksey


JSW Steel Q4 Result Review: Volume Growth Intact, Margin Expansion To Continue, Says Systematix— Maintains Buy


Mankind Pharma Q4 Review: Miss On Operating Performance, Dolat Capital Maintains 'Add' But Cuts Target Price
